Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient

Massimiliano Lanzafame, Emanuela Lattuada, Stefano Nicolè, Fabio Rigo, Giulia Cucchetto, Ercole Concia, Sandro Vento

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Highly active antiretroviral therapy (HAART) has changed the natural course of HIV infection. However, the toxicities associated with long-term use of nucleoside reverse transcriptase inhibitors (NRTIs) have led to the assessment of dual-therapy approaches with less toxicity. Atazanavir and dolutegravir have antiviral potency, tolerability and favourable metabolic profile. In suppressed HIV-infected patients, with NRTIs-related toxicity effects, the association of atazanavir and dolutegravir, favoured by their positive pharmacokinetics interaction, could be used as ‘maintenance’ antiretroviral therapy. We report a case report about one HIV-infected patient, on HAART and with a persistent suppression of HIV RNA, switched to dolutegravir 50 mg three times weekly plus atazanavir 400 mg once daily, as ‘maintenance antiretroviral therapy’, with persistence of viral suppression.

Original languageEnglish
Pages (from-to)726-728
Number of pages3
JournalInternational Journal of STD and AIDS
Volume28
Issue number7
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Reverse Transcriptase Inhibitors
Highly Active Antiretroviral Therapy
HIV
Nucleosides
Maintenance
Metabolome
HIV Infections
Antiviral Agents
Therapeutics
Pharmacokinetics
RNA
dolutegravir
Atazanavir Sulfate

Keywords

  • Atazanavir
  • dolutegravir
  • maintenance antiretroviral therapy
  • pharmacokinetics

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient. / Lanzafame, Massimiliano; Lattuada, Emanuela; Nicolè, Stefano; Rigo, Fabio; Cucchetto, Giulia; Concia, Ercole; Vento, Sandro.

In: International Journal of STD and AIDS, Vol. 28, No. 7, 01.01.2017, p. 726-728.

Research output: Contribution to journalArticle

Lanzafame, Massimiliano ; Lattuada, Emanuela ; Nicolè, Stefano ; Rigo, Fabio ; Cucchetto, Giulia ; Concia, Ercole ; Vento, Sandro. / Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient. In: International Journal of STD and AIDS. 2017 ; Vol. 28, No. 7. pp. 726-728.
@article{3defd8e72ecb405eb0554ca921f18de8,
title = "Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient",
abstract = "Highly active antiretroviral therapy (HAART) has changed the natural course of HIV infection. However, the toxicities associated with long-term use of nucleoside reverse transcriptase inhibitors (NRTIs) have led to the assessment of dual-therapy approaches with less toxicity. Atazanavir and dolutegravir have antiviral potency, tolerability and favourable metabolic profile. In suppressed HIV-infected patients, with NRTIs-related toxicity effects, the association of atazanavir and dolutegravir, favoured by their positive pharmacokinetics interaction, could be used as ‘maintenance’ antiretroviral therapy. We report a case report about one HIV-infected patient, on HAART and with a persistent suppression of HIV RNA, switched to dolutegravir 50 mg three times weekly plus atazanavir 400 mg once daily, as ‘maintenance antiretroviral therapy’, with persistence of viral suppression.",
keywords = "Atazanavir, dolutegravir, maintenance antiretroviral therapy, pharmacokinetics",
author = "Massimiliano Lanzafame and Emanuela Lattuada and Stefano Nicol{\`e} and Fabio Rigo and Giulia Cucchetto and Ercole Concia and Sandro Vento",
year = "2017",
month = "1",
day = "1",
doi = "10.1177/0956462416678164",
language = "English",
volume = "28",
pages = "726--728",
journal = "International Journal of STD and AIDS",
issn = "0956-4624",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient

AU - Lanzafame, Massimiliano

AU - Lattuada, Emanuela

AU - Nicolè, Stefano

AU - Rigo, Fabio

AU - Cucchetto, Giulia

AU - Concia, Ercole

AU - Vento, Sandro

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Highly active antiretroviral therapy (HAART) has changed the natural course of HIV infection. However, the toxicities associated with long-term use of nucleoside reverse transcriptase inhibitors (NRTIs) have led to the assessment of dual-therapy approaches with less toxicity. Atazanavir and dolutegravir have antiviral potency, tolerability and favourable metabolic profile. In suppressed HIV-infected patients, with NRTIs-related toxicity effects, the association of atazanavir and dolutegravir, favoured by their positive pharmacokinetics interaction, could be used as ‘maintenance’ antiretroviral therapy. We report a case report about one HIV-infected patient, on HAART and with a persistent suppression of HIV RNA, switched to dolutegravir 50 mg three times weekly plus atazanavir 400 mg once daily, as ‘maintenance antiretroviral therapy’, with persistence of viral suppression.

AB - Highly active antiretroviral therapy (HAART) has changed the natural course of HIV infection. However, the toxicities associated with long-term use of nucleoside reverse transcriptase inhibitors (NRTIs) have led to the assessment of dual-therapy approaches with less toxicity. Atazanavir and dolutegravir have antiviral potency, tolerability and favourable metabolic profile. In suppressed HIV-infected patients, with NRTIs-related toxicity effects, the association of atazanavir and dolutegravir, favoured by their positive pharmacokinetics interaction, could be used as ‘maintenance’ antiretroviral therapy. We report a case report about one HIV-infected patient, on HAART and with a persistent suppression of HIV RNA, switched to dolutegravir 50 mg three times weekly plus atazanavir 400 mg once daily, as ‘maintenance antiretroviral therapy’, with persistence of viral suppression.

KW - Atazanavir

KW - dolutegravir

KW - maintenance antiretroviral therapy

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85019020470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019020470&partnerID=8YFLogxK

U2 - 10.1177/0956462416678164

DO - 10.1177/0956462416678164

M3 - Article

C2 - 27789848

AN - SCOPUS:85019020470

VL - 28

SP - 726

EP - 728

JO - International Journal of STD and AIDS

JF - International Journal of STD and AIDS

SN - 0956-4624

IS - 7

ER -